title: [In vivo study of the pharmacokinetic interaction of afobazole and losartan (cytochrome CYP2C9 substrate)].
abstract: The influence of afobazole on isoenzyme CYP2C9 production in rats was studied using losartan as the marker drug. Single dose of losartan was administered orally without afobazole in a dose of 30 mg/kg and in the same single (30 mg/kg) on the background of 3- and 4-day administration of afobazole in a dose of 5, 25, 75, 100, and 125 mg/kg. At 5 mg/kg (effective dose for anxiolytic effect), afobazole did not cause any induction/inhibition effect on CYP2C9 isoenzyme. A multiple increase in afobazole dose was manifested by a moderate induction effect. The maximum induction effect of afobazole was achieved in a dose of 75 mg/kg. At doses above 75 mg/kg, the induction effect of afobazole was less pronounced.
authors.forename: O G
authors.initials: OG
authors.lastname: Gribakina
authors.forename: G B
authors.initials: GB
authors.lastname: Kolyvanov
authors.forename: A A
authors.initials: AA
authors.lastname: Litvin
authors.forename: V P
authors.initials: VP
authors.lastname: Zherdev
authors.forename: S B
authors.initials: SB
authors.lastname: Seredin
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001562:Benzimidazoles / Q000493:pharmacokinetics* / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects; D019808:Losartan / Q000493:pharmacokinetics* / Q000494:pharmacology; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats
chemical_list: C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D009025:Morpholines; D003577:Cytochrome P-450 Enzyme System; C507848:CYP2C9 protein, rat; D019808:Losartan